Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 1, 2016, Pages 114-124

  Ura, K ^a,b   Furusyo, N ^a,b   Ogawa, E ^a,b   Hayashi, T ^a   Mukae, H ^a   Shimizu, M ^a   Toyoda, K ^a   Murata, M ^a,b   Hayashi, J ^c  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Kyushu General Internal Medicine Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; ANTIVIRUS AGENT; BINDING PROTEIN; INTERLEUKIN 28B; MAC 2 BINDING PROTEIN; PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; WFA M2BP; ALPHA INTERFERON; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINE RECEPTOR; OLIGOPEPTIDE; PEGINTERFERON ALPHA2B; PLANT LECTIN; RECOMBINANT PROTEIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; WISTERIA LECTIN;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY;

AGED; ANTIGENS, NEOPLASM; ANTIVIRAL AGENTS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OLIGOPEPTIDES; PLANT LECTINS; POLYETHYLENE GLYCOLS; RECEPTORS, N-ACETYLGLUCOSAMINE; RECOMBINANT PROTEINS; SIMEPREVIR; TREATMENT OUTCOME;

EID: 84951907013     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13431     Document Type: Article

References (33)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
2. Poynard T, Moussalli J, Munteanu M, et al,. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675-83.
3. Ogawa E, Furusyo N, Kajiwara E, et al,. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58: 495-501.
4. Rutter K, Stättermayer AF, Beinhardt S, et al,. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther 2015; 41: 521-31.
5. Furusyo N, Ogawa E, Nakamuta M, et al,. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59: 205-12.
6. Furusyo N, Ogawa E, Murata M, et al,. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J Antimicrob Chemother 2014; 69: 483-90.
7. Ogawa E, Furusyo N, Shimizu M, et al,. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. Antiviral Ther 2015; 20: 185-92.
8. Kuno A, Ikehara Y, Tanaka Y, et al,. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013; 3: 1065.
9. Toshima T, Shirabe K, Ikegami T, et al,. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol 2015; 50: 76-84.
10. Umemura T, Joshita S, Sekiguchi T, et al,. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol 2015; 110: 857-64.
11. Yamasaki K, Tateyama M, Abiru S, et al,. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60: 1563-70.
12. Tamaki N, Kurosaki M, Kuno A, et al,. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res 2015. doi: 10.1111/hepr.12466
13. Fujiyoshi M, Kuno A, Gotoh M, et al,. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015. doi: 10.1007/s00535-015-1063-2
14. Hanai T, Shiraki M, Ohnishi S, et al,. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res 2015. doi: 10.1111/hepr.12473
15. Simmonds P, Alberti A, Alter HJ, et al,. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
16. Ogawa E, Furusyo N, Murata M, et al,. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. J Hepatol 2012; 57: 534-40.
17. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
18. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
19. Vallet-Pichard A, Mallet V, Nalpas B, et al,. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection: comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
20. Lin ZH, Xin YN, Dong QJ, et al,. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-36.
21. Ogawa E, Furusyo N, Toyoda K, et al,. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83: 127-34.
22. Kuno A, Sato T, Shimazaki H, et al,. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl 2013; 7: 642-7.
23. Artini M, Natoli C, Tinari N, et al,. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25: 212-7.
24. Regev A, Berho M, Jeffers LJ, et al,. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
25. Ichikawa S, Motosugi U, Ichikawa T, et al,. Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C. Magn Reson Med Sci 2012; 11: 291-7.
26. Thein HH, Yi Q, Dore GJ, et al,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.
27. Kurosaki M, Tanaka Y, Nishida N, et al,. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54: 439-48.
28. Ogawa E, Furusyo N, Kajiwara E, et al,. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. Antiviral Res 2014; 104: 102-9.
29. Ogawa E, Furusyo N, Nakamuta M, et al,. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther 2013; 38: 1076-85.
30. Backus LI, Belperio PS, Shahoumian TA, et al,. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93-103.
31. Ogawa E, Furusyo N, Kajiwara E, et al,. Comparative safety study on severe anemia by simeprevir-versus telaprevir-based triple therapy for chronic hepatitis C. J Gastroenterol Hepatol 2015; 30: 1309-16.
32. Ogawa E, Furusyo N, Kajiwara E, et al,. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol 2015. doi: 10.1111/jgh.13016
33. Joffe MM, Rosenbaum PR,. Invited commentary: propensity scores. Am J Epidemiol 1999; 150: 327-33.